InnoCare Pharma Limited
INCPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.07 | 1.63 | -0.02 | 6.23 |
| FCF Yield | -1.10% | -2.35% | -2.81% | -0.00% |
| EV / EBITDA | -112.88 | -63.11 | -31.95 | -190.64 |
| Quality | ||||
| ROIC | -6.14% | -7.17% | -8.14% | -8.47% |
| Gross Margin | 86.29% | 82.61% | 77.07% | 93.70% |
| Cash Conversion Ratio | 0.81 | 1.04 | 0.63 | -8.30 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.30% | -10.87% | 671.11% | 842.20% |
| Free Cash Flow Growth | 52.08% | 1.06% | -8,507,909.09% | 100.00% |
| Safety | ||||
| Net Debt / EBITDA | 15.84 | 13.31 | 9.21 | 27.87 |
| Interest Coverage | -15.56 | -18.59 | -45.20 | -68.55 |
| Efficiency | ||||
| Inventory Turnover | 1.45 | 1.08 | 2.20 | 6.62 |
| Cash Conversion Cycle | 47.77 | 91.66 | -61.00 | -399.28 |